Topic Compatibility Lactoserum (Dermacyd Delicata - New Fragrance)

The purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd Femina Delicata.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hygiene

Age range

18 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Sanofi-aventis

São Paulo, Brazil

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Phototypes: I, II, III and IV
Integral skin test in the region

Exclusion criteria

Pregnancy or breastfeeding women
Use of antinflammatory or immune-suppression drugs
Personal history of atopy
History of sensibilization or irritation for topic products
Active cutaneous disease
Use of new drugs and/or cosmetics during the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

lactoserum

Drug

Primary outcomes

Score evaluation of the cutaneous reaction, preconized by International Contact Dermatitis Research Group (ICDRG)

Time frame: six weeks

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensitivity) for Dermacyd Femina Delicata

Important dates

Study start: 2007
First posted: Jul 9, 2007
Registry last updated: May 20, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed